Skip to main content
profile image
Selected Works of Shu-Ching Chang, PhD, MS
Article
A phase Ib study of pre-operative, locoregional IRX-2 cytokine immunotherapy to prime immune responses in patients with early stage breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
  • David B Page, Providence Cancer Center, Earle A. Chiles Research Institute Portland , OR , USA
  • Joanna Pucilowska, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR
  • Katherine G Sanchez, Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Institute
  • Alison K Conlin
  • Anupama Acheson, Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Institute
  • Kelly S Perlewitz, Providence Cancer Institute, Newberg, OR, USA.
  • James H Imatani, Providence Portland Surgical Specialists, Earle A. Chiles Research Institute, Providence Cancer Institute
  • Shagheyegh Aliabadi-Wahle, Earle A. Chiles Research Institute, Portland, OR; Providence Cancer Institute, Portland, OR
  • Nikki Moxon, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR
  • Staci Mellinger, Earle A. Chiles Research Institute, Portland, OR; Providence Cancer Institute, Portland, OR
  • Amanda Y Seino, Medical Oncology, Earle A. Chiles Research Institute, Providence Cancer Institute
  • Maritza Martel, Providence Portland Medical Center, Portland, OR
  • Yaping Wu, Pathology, Providence Portland Medical Center
  • Zhaoyu Sun, Earle A. Chiles Research Institute, Providence Portland Medical Center
  • William L Redmond, Earle A Chiles Research Institute
  • Valerie Conrad, Earle A. Chiles Research Institute, Portland, OR; Providence Cancer Institute, Portland, OR
  • Venkatesh Rajamanickam, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR
  • Dottie Waddell, Earle A. Chiles Research Institute, Providence Cancer Institute
  • Deborah Laxague, Cancer Center, Earle A. Chiles Research Institute, Providence Cancer Institute
  • Monil Shah
  • Shu-Ching Chang, Medical Data Research Center, Providence Health & Services, Portland, OR, USA
  • Walter Urba, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, 97213, USA.
Link
Document Type
Article
Publication Date
12-12-2019
Disciplines
Abstract

PURPOSE: To evaluate the safety and feasibility of pre-operative locoregional cytokine therapy (IRX-2 regimen) in early stage breast cancer, and to evaluate for intratumoral and peripheral immunomodulatory activity.

EXPERIMENTAL DESIGN: Sixteen patients with stage I-III early stage breast cancer (any histology type) indicated for surgical lumpectomy or mastectomy were enrolled to receive pre-operative locoregional immunotherapy with the IRX-2 cytokine biologic (2mL subcutaneous x 10 days to peri-areolar skin). The regimen also included single-dose cyclophosphamide (300mg/m

RESULTS: Pre-operative locoregional cytokine administration was feasible in 100% (n=16/16) of subjects and associated with increases in stromal tumor-infiltrating lymphocytes (p

CONCLUSIONS: IRX-2 is safe in early stage breast cancer. Potentially favorable immunomodulatory changes were observed, supporting further study of IRX-2 in early stage breast cancer and other malignancies.

Clinical Institute
Cancer
Clinical Institute
Women & Children
Department
Oncology
Department
Earle A. Chiles Research Institute
Citation Information
David B Page, Joanna Pucilowska, Katherine G Sanchez, Alison K Conlin, et al.. "A phase Ib study of pre-operative, locoregional IRX-2 cytokine immunotherapy to prime immune responses in patients with early stage breast cancer." Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Available at: http://works.bepress.com/shu-ching-chang/36/